Apalutamide in addition to androgen deprivation therapy (ADT) maintains health-related quality of life in Phase III TITAN study

The patient-reported outcomes data (assessed using BPI-SF and FACT-P questionnaire) from prespecified final analysis of the study in patients with metastatic hormone-sensitive prostate cancer also showed addition of apalutamide to ADT did not worsen side effect burden.

Source:

PharmaTimes